Janux Therapeutics

Thank you ZERO Prostate Cancer and #TeamJanux for a great ZERO Prostate Cancer Run/Walk in San Diego! It was the perfect way to conclude Prostate Cancer Awareness Month, and we were proud to support the event as a gold sponsor. At Janux Therapeutics, we're committed to advancing the fight against prostate cancer through innovative new immunotherapies. We are focused on creating safer, more effective treatments to improve patient outcomes and bring new hope to those battling this disease. Together, we're making strides in the community and in the clinic toward a future with #ZEROProstateCancer. #GoJanux #PCAM #pcsm #prostatecancer #mCRPC #ProstateCancerAwareness

Whether tackling a major project or pursuing a personal goal, commitment is the driving force that keeps Ying Zhang motivated and pushes her to overcome challenges when things get tough or lose their initial excitement. It's a value we share here at Janux. The talented proteomics expert recently reflected on how a shared commitment to improving patient lives drives the work of her and her team. Thanks for sharing your insights, Ying! #Culture #LeadByExample #CoreValues #LifeatJanux #commitment

Each day, we work to develop meaningful new immunotherapies to improve the treatment of prostate cancer. We also know that early detection is important to better outcomes. Establishing a prostate cancer screening schedule depends on individual risk factors and family history. During Prostate Cancer Awareness Month, we encourage families to discuss their family medical history, and suggest that all the men read up on when to get tested as part of a precision screening process. During #PCAM, we are also proud to participate in the San Diego Run/Walk on September 28th for the ZERO Prostate Cancer patient support network. 💡 Find out when to get checked with this great Prostate Cancer Foundation resource: https://lnkd.in/e4ETdpJq 👟 Sign up for the walk: https://lnkd.in/gcaUhzsX  📚 Learn more about the work we are doing to develop new immunotherapies for #prostatecancer: https://lnkd.in/g7ewWXwB #mCRPC #ZEROout #ProstateCancerAwareness

Today we reported our second quarter (Q2) financial results and business highlights. Enrollment is ongoing for PSMA-TRACTr (JANX007) in prostate cancer and for EGFR-TRACTr (JANX008) in solid tumors. An update on JANX007 data and doses selected for expansion cohorts is anticipated in 2H 2024. Also, Janux received a $7.5 million payment from Merck triggered by the achievement of an undisclosed development milestone for the first collaboration target under the companies’ 2020 Research Collaboration and Exclusive License Agreement.   Read the press release for more:  https://lnkd.in/gch68RvQ    #Q2Earnings #ProstateCancer #cancer #TRACTr #TRACIr #TCellEngagers

Congratulations to Janux CEO, President & Cofounder David Campbell and Chief Scientific Officer & Cofounder Thomas DiRaimondo for being recognized as San Diego Business Journal’s 2024 Leaders of Influence in Life Sciences.    We are proud to celebrate their leadership and commitment to our mission to create new medicines that improve how #cancer is treated. Thank you for all you do #EveryDayatJanux. 👏👏👏👏 See the full list here: https://lnkd.in/g4EVhRvE    #TeamJanux #Leadership #Lifesciences #YearAwards #SDBJ

Recharging is essential! For the first week in July we took a synchronous #summervacation to allow us to return refreshed and renewed to carry on our mission. See below for some photos from #TeamJanux showing our adventures & activities! #EmployeeWellness #WorkLifeBalance

We are pleased to welcome Eric Dobmeier and Natasha Hernday to our Board of Directors. Their vast experience and proven leadership in the biopharmaceutical industry are tremendous assets for Janux at this pivotal stage of our growth. Today, we also announced the resignation of Jay Lichter from the Board. We are grateful to Jay, a key figure as the head of Janux’s founding seed investor Avalon Ventures, who has been instrumental in the company’s growth and success. Current Board member Ronald W. Barrett will replace Jay as Chairperson of the Board. We look forward to Ron’s continued stewardship and contributions as we advance our pipeline of innovative #TCellEngagers as next-generation immunotherapies to improve the treatment of #cancer. Read the release here:  https://lnkd.in/dPWE5Q4T

We are so proud of #TeamJanux, and we appreciate all the hard work you do #EveryDayatJanux in our mission to create new medicines that improve how cancer is treated. For Employee Appreciation Week, we shared with each other how each of us makes an impact, not only for our team, but also in the lives of patients. Together, we are making a difference! 

For Fabrece Roup, collaboration isn't a buzzword. It's an integral part of his job as a researcher. Hear why this particular value speaks to him, and how the diverse sets of skills, knowledge, and creativity at Janux inspire and motivate him to achieve more each day to address the unmet needs of cancer patients. #Culture #CoreValues #science #LifeAtJanux #collaboration #oncology #cancer

Today we reported our first quarter (Q1) financial results and business highlights. Enrollment is ongoing for PSMA-TRACTr (JANX007) in prostate cancer and for EGFR-TRACTr (JANX008) in solid tumors. JANX007 data and doses selected for expansion cohorts is anticipated in 2H 2024.   Read the press release for more: https://lnkd.in/gV796Htw    #Q1Earnings #ProstateCancer #cancer #TRACTr #TRACIr #TCellEngagers